LOXL1 and prostate carcinoma: The lncRNA LOXL1-AS1, upregulated in doxorubicin-resistant prostate cancer DU-145 cells, increases cell proliferation and migration, while reducing apoptosis, implicating the LOXL1-AS1/miR-let-7a-5p/EGFR axis in drug resistance [164].